

Materials for this course will release 03/30/2022

Ambulatory Care Pharmacy Specialty Review Course, Workbook Chapters, and Practice exam (No Recert Credit (Cert # L229164))

Teaser: This online Specialty Review Course, workbook chapters, and practice exam package will help you prepare for the Board of Pharmacy Specialty (BPS) examination. With this course, get comprehensive, practical guidance, with a variety of complex cases, including references for further study.

Tag: Certifications; Ambulatory Care



ACPE Numbers: Various – see listing below

Pre-Sale Date: 03/17/2022

Content Release Date: 03/30/2022

Expiration Date: 02/14/2023

Activity Type: Application-based

CE Credits: 24.5 contact hours (ACPE only)

Activity Fee: \$425 (ASHP member); \$625 (non-member)

Accreditation for Pharmacists



The American College of Clinical Pharmacy (ACCP) and the American Society of Health-System Pharmacists (ASHP) are accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Target Audience

These activities are intended for pharmacists who are seeking to update their knowledge and skills commensurate with a board certification examination in the areas listed below.

Activity Overview

Ambulatory Care Pharmacy Preparatory Review and Recertification Course is designed to help pharmacists who are preparing for the Board of Pharmacy Specialties certification examination in Ambulatory Care Pharmacy as well as those seeking a general review and refresher on disease states and therapeutics. The program goals are as follows:

- To present a high-quality, up-to-date overview of disease states and therapeutics;
- To provide a framework to help attendees prepare for the specialty certification examination in ambulatory care pharmacy; and
- To offer participants an effective learning experience using a case-based approach with a strong focus on the thought processes needed to solve patient care problems in each therapeutic area.

This course is **NOT** intended for those obtaining recertification credit. To earn recertification credit, please see courses here: <http://elearning.ashp.org/catalog/amb-care-recert>

These activities are part of the ACCP and ASHP professional development program.

Materials for this course will release 03/30/2022

REVIEW COURSE

This course consists of 19 activities (see table below) and provides up to 24.5 contact hours of continuing pharmacy education credit. The Review Course includes case-based presentations for application to real-life scenarios, workbook, a practice exam along with correct answers, and links to the reference sources, and domains, tasks, and knowledge statements. To help you further prepare, this package includes a compilation of practice questions in the same format and rigor to help you prepare for the BPS Specialty Examination.

For full program information, please visit: <http://elearning.ashp.org/catalog/amb-care-review>

Learning Module	ACPE Number	Credit Hours	ACPE Expiration Date
Trial Design and Biostatistics - Module IA	0217-9999-22-050-H04-P	2.5	03/03/25
Endocrine Disorders - Module IB	0217-9999-22-051-H01-P	1.5	03/03/25
Genitourinary, Electrolytes, and Nutritional Deficiencies/Supplementation in Older Adults - Module 1C	0217-9999-22-049-H01-P	1	03/03/25
Cardiology I - Module 2A	0217-9999-22-052-H01-P	1.5	03/03/25
Cardiology II - Module 2B	0217-9999-22-053-H01-P	1.5	03/03/25
Bone/Joint and Rheumatology - Module 2C	0217-9999-22-054-H01-P	1	03/03/25
Diabetes Mellitus - Module 3A	0217-9999-22-055-H01-P	1.5	03/03/25
Obstetrics and Gynecology - Module 3B	0217-9999-22-056-H01-P	1.5	03/03/25
Pulmonary Disorders - Module 3C	0217-9999-22-057-H01-P	1	03/03/25
Practices and Processes of Care - Module 4A	0217-9999-22-058-H04-P	1	03/03/25
Communication Strategies in Pharmacy - Module 4B	0217-9999-22-059-H04-P	1	03/03/25
Developing and Managing a Clinical Practice - Module 4C	0217-9999-22-060-H04-P	1.5	03/03/25
Psychiatric Disorders - Module 5A	0217-9999-22-061-H01-P	1.5	03/03/25
Neurology - Module 5B	0217-9999-22-062-H01-P	1	03/03/25
Gastrointestinal Disorders - Module 5C	0217-9999-22-063-H01-P	1.5	03/03/25
Infectious Diseases I - Module 6A	0217-9999-22-064-H02-P	1	03/03/25
Infectious Diseases II - Module 6B	0217-9999-22-065-H01-P	1	03/03/25
Nephrology - Module 6C	0217-9999-22-066-H01-P	1	03/03/25
Dermatologic and Eyes, Ears, Nose, and Throat, and Immunologic Disorders - Module 6D	0217-9999-22-067-H01-P	1	03/03/25

Materials for this course will release 03/30/2022

Learning Objectives

At the end of the presentations, the pharmacist should be able to:

Trial Design and Biostatistics - Module IA

ACPE #: 0217-9999-22-050-H04-P

- Describe hypothesis testing and state the meaning of and distinguish between p values and confidence intervals, and measures of central tendency and data spread.
- Define, compare, and contrast the concepts of internal and external validity, causation, association, bias, and confounding in trial design. Select strategies to eliminate or control for bias and improve internal and external validity.
- Compare and contrast the advantages and disadvantages of various study designs (e.g., prospective, retrospective, case-control, cohort, cross-sectional, randomized controlled clinical trials, systematic review, meta-analysis).
- Determine why a statistical test is appropriate or not appropriate, given the sample distribution, data type, and study design. Interpret statistical and clinical significance for results from commonly used statistical tests.
- Define and evaluate odds ratio, risk/incidence rate, relative risk, number needed to treat, number needed to harm, and other risk estimates.

Endocrine Disorders - Module IB

ACPE #: 0217-9999-22-051-H01-P

- Identify appropriate thyroid hormone replacement therapy dosing strategies for patients with hypothyroidism and hyperthyroidism.
- Recommend appropriate patient-specific pharmacotherapy for the treatment of polycystic ovary syndrome.
- Medically manage a patient with hyperprolactinemia, acromegaly, and growth hormone deficiency.
- Differentiate between available weight-loss medications and design a patient-specific treatment plan.
- Recognize the clinical presentation, and design a treatment plan for, a patient with adrenal gland disorders and Cushing disease.
- Compare available testosterone (T) replacement products and list appropriate monitoring guidelines for hypogonadism.

Genitourinary, Electrolytes, and Nutritional Deficiencies/Supplementation in Older Adults - Module 1C

ACPE #: 0217-9999-22-049-H01-P

- Identify and assess common genitourinary diseases, electrolyte abnormalities, and nutritional deficiencies in ambulatory older adults.
- Evaluate and manage drug-induced causes of benign prostatic hyperplasia (BPH), urinary incontinence, erectile dysfunction (ED), electrolyte abnormalities, and nutritional deficiencies in ambulatory older adults.
- Compare and contrast pharmacologic interventions for BPH, urinary incontinence, ED, electrolyte abnormalities, and nutritional deficiencies.
- Formulate treatment strategies for BPH, urinary incontinence, ED, electrolyte abnormalities, and nutritional deficiencies using patient-specific information.

Cardiology I - Module 2A

ACPE #: 0217-9999-22-052-H01-P

- Evaluate the appropriate use of aspirin for primary prevention of cardiovascular (CV) events according to practice guidelines and clinical trial evidence.
- Design an evidence-based treatment and monitoring strategy for patients with hypertension (HTN) that considers goals of therapy, comorbid conditions, and compelling indications.

Materials for this course will release 03/30/2022

- Create an evidence-based treatment and monitoring plan for patients receiving lipid-lowering therapies for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD) and hypertriglyceridemia.
- Devise an evidence-based treatment plan for secondary prevention of acute coronary syndrome (ACS), stroke and transient ischemic attack (TIA), and peripheral arterial disease (PAD).

Cardiology II - Module 2B

ACPE #: 0217-9999-22-053-H01-P

- Formulate appropriate oral anticoagulant treatment strategies for patients who develop venous thromboembolism (deep venous thrombosis or pulmonary embolism), nonvalvular atrial fibrillation, or who have mechanical heart valves consistent with available consensus panel guidelines, recent U.S. Food and Drug Administration approvals, and randomized clinical trials.
- Describe key differences in onset of action, dosing, administration, absorption, effects on common coagulation tests, and drug interactions between dabigatran, rivaroxaban, apixaban, edoxaban, and warfarin.
- Develop patient-specific, guideline-driven treatment, monitoring, and follow-up plans for patients with heart failure, atrial fibrillation, or ventricular tachycardia.
- Identify treatment goals, common adverse effects, clinically important drug interactions, monitoring, and risk evaluation and mitigation strategies requirements for oral pharmacotherapy of pulmonary arterial hypertension.

Bone/Joint and Rheumatology - Module 2C

ACPE #: 0217-9999-22-054-H01-P

- Systematically identify patients to screen for osteoporosis, and use the screening results to guide the decision on how to treat the patient.
- Use a STEPS-wise approach (safety, tolerability, efficacy, preference [pearls], simplicity) for comparing, recommending, and justifying a drug therapy regimen for osteoporosis, rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA), fibromyalgia, gout, and systemic lupus erythematosus (SLE).
- Choose a drug therapy for OA or fibromyalgia syndrome on the basis of drug efficacy and a patient's comorbid conditions.
- Select screenings or laboratory tests at correct intervals for patients with RA, PsA, or SLE treated with disease-modifying antirheumatic drug (DMARD) or biologic DMARD therapies.
- Formulate a care plan to help patients decrease their uric acid concentrations, gout symptoms, and gouty attacks using nonpharmacologic and pharmacologic interventions.

Diabetes Mellitus - Module 3A

ACPE #: 0217-9999-22-055-H01-P

- Identify differences between prediabetes, type 1 diabetes mellitus (T1DM), type 2 diabetes mellitus (T2DM), and gestational diabetes mellitus (GDM), including differences in diagnostic criteria and clinical presentation.
- Describe the pathophysiology of T1DM and T2DM.
- Compare agents used in the treatment of diabetes mellitus (DM), including their mechanisms of action, adverse effects, contraindications, advantages, and disadvantages.
- Select appropriate insulin regimens for patients on the basis of desired onset, peak, and duration of insulin effects.
- Individualize a comprehensive glycemic treatment and monitoring plan for a patient with prediabetes, DM, and GDM.
- Discuss appropriate blood pressure and lipid management for patients with DM.
- Discuss the acute and chronic complications associated with DM and strategies to prevent them or slow their progression.

Materials for this course will release 03/30/2022

Obstetrics and Gynecology - Module 3B

ACPE #: 0217-9999-22-056-H01-P

- Recommend therapy for contraception, infertility, menstrual disorders, endometriosis, and symptoms of menopause on the basis of patient-specific information.
- Recommend appropriate treatment for common acute and chronic conditions in pregnancy and lactation.
- Recommend therapy for menopause on the basis of patient-specific information.
- Develop provider and patient education regarding medication use during pregnancy and lactation, contraception, infertility, menstrual disorders, endometriosis, and postmenopausal therapy.

Pulmonary Disorders - Module 3C

ACPE #: 0217-9999-22-057-H01-P

- Compare and contrast between common features of patients with asthma or chronic obstructive pulmonary disease (COPD).
- Select appropriate evidence-based treatment for patients with asthma, COPD, and/or nicotine dependence based on specific patient factors and comorbidities.
- Develop a comprehensive education plan with monitoring parameters for patients on therapy for asthma, COPD, and/or smoking cessation.
- Compare and contrast the different respiratory inhaler devices and holding chambers.
- Integrate brief behavioral counseling and smoking cessation best practices when assisting a patient with quitting smoking.

Practices and Processes of Care - Module 4A

ACPE #: 0217-9999-22-058-H04-P

- Discuss issues with transitions of care, including a pharmacist's role in achieving quality measures and improving the process.
- Describe different types of patient care services or practice models provided by a pharmacist within an ambulatory practice, along with any applicable regulatory requirements.
- Apply tools and resources to detect, classify, report, analyze, and reduce preventable and non-preventable adverse drug events.
- Use formulary management activities and other resources to improve the prescribing of safe, effective, and affordable treatments in an organization.

Communication Strategies in Pharmacy - Module 4B

ACPE #: 0217-9999-22-059-H04-P

- Use strategies that develop patient rapport, foster trust, and effectively and efficiently obtain accurate, comprehensive histories, despite potential barriers in communication.
- Use assessments of patients' knowledge, health literacy, self-management skills, health beliefs, and attitudes toward medications to tailor educational interventions that will improve adherence and self-efficacy.
- Communicate patient care activities and medication-related information effectively to other health care professionals verbally and in writing through the medical record.
- Discuss factors and methods used to assess and select appropriate written educational materials intended for the general public.

Materials for this course will release 03/30/2022

Developing and Managing a Clinical Practice - Module 4C

ACPE #: 0217-9999-22-060-H04-P

- Perform an internal and external environmental scan and needs assessment to determine the need for and organizational value of an ambulatory pharmacist–provided patient care service.
- Discuss steps to implement an ambulatory service, including identifying key stakeholders and developing essential clinic operational activities.
- Develop a robust and sustainable quality assessment program using the balanced scorecard concept for your clinical service and identifying quality measures important to your organization and patient population.
- Develop a credentialing and privileging process to ensure the competency of pharmacists providing direct patient care in your ambulatory service.
- Identify and implement revenue-generating opportunities for pharmacist-provided patient care services in different ambulatory care settings.

Psychiatric Disorders - Module 5A

ACPE #: 0217-9999-22-061-H01-P

- Analyze the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria and disease course for anxiety disorders, sleep disorders, major depression, bipolar disorder, attention-deficit/hyperactivity disorder, schizophrenia, and substance use disorders.
- Apply a working knowledge of common drug and nondrug therapies for psychiatric disorders, including drug, dose, frequency, adverse effects, drug interactions, and monitoring values.
- Recommend appropriate treatments, including both lifestyle modification and specific drug therapy (medication dose, schedule, and delivery system), on the basis of relevant patient factors (pharmacodynamic, physiologic, pharmacokinetic, and socioeconomic parameters).
- Monitor for adverse drug effects, drug-drug and drug-disease interactions, and appropriateness of therapy, including polytherapy.

Neurology - Module 5B

ACPE #: 0217-9999-22-062-H01-P

- Given a patient case, select an appropriate antiepileptic drug (AED) regimen for a patient with epilepsy on the basis of seizure type and AED mechanism of action, common adverse effects, and drug interactions.
- Recommend an appropriate pharmacologic therapy for a patient with episodic or chronic migraine headache.
- Recommend and manage appropriate disease-modifying therapy for a patient with multiple sclerosis (MS) on the basis of MS subtype and other patient-specific factors.
- Recommend an appropriate pharmacologic therapy for a patient with Parkinson disease, neuropathic pain, or Alzheimer disease.

Gastrointestinal Disorders - Module 5C

ACPE #: 0217-9999-22-063-H01-P

Gastrointestinal (GI) disorders within the objectives refer to the disorders covered in this chapter and include the following: gastroesophageal reflux disease, peptic ulcer disease, chronic liver disease manifestations, viral hepatitis, malabsorption syndrome, diarrhea, constipation, nausea and vomiting, irritable bowel syndrome, and inflammatory bowel disease.

- Apply national guideline–based treatment strategies for gastrointestinal (GI) disorders.
- Assess the benefits and risks of drug therapy for patients with GI disorders.
- Recommend appropriate nonpharmacologic and pharmacologic interventions for managing GI disorders.
- Develop and implement a patient-specific comprehensive therapeutic plan for managing GI disorders.
- Provide drug-related patient education and counseling for pharmacologic therapies used in managing GI disorders.

Materials for this course will release 03/30/2022

Infectious Diseases I - Module 6A

ACPE #: 0217-9999-22-064-H02-P

- Identify the clinical presentations of sexually transmitted infections, and design appropriate treatment regimens.
- Describe the mechanisms of action and adverse effects associated with antiretroviral agents, and identify major drug interactions associated with them.
- Formulate treatment strategies for the management of HIV and commonly encountered opportunistic infections.
- Design appropriate strategies for treatment and prevention of influenza and other viral infections.
- Explain the risk factors for superficial and endemic fungal infections, and design corresponding treatment regimens.

Infectious Diseases II - Module 6B

ACPE #: 0217-9999-22-065-H01-P

- Design appropriate pharmacologic and nonpharmacologic treatment regimens for patients with urinary tract infections, prostatitis, community-acquired pneumonia, sinusitis, pharyngitis, acute otitis media, skin and soft tissue infections, latent tuberculosis infection, conjunctivitis, Lyme disease, antibiotic prophylaxis, infectious diarrhea, and *Clostridioides difficile* infections.
- Identify risk factors and clinical circumstances for antimicrobial resistance.
- Design an antimicrobial therapeutic regimen to treat resistant infections and prevent their future development.
- Apply evidence-based medicine and patient-specific factors to design antimicrobial regimens that are appropriate and cost-effective for the patient.

Nephrology - Module 6C

ACPE #: 0217-9999-22-066-H01-P

- Identify a patient at risk of developing, or presenting with, acute kidney injury, drug-induced kidney disease, or chronic kidney disease (CKD), and formulate an appropriate care plan to mitigate risk and slow progression.
- Using appropriate data, assess kidney function, dialysis regimen information, and pharmacokinetic/pharmacodynamic drug properties in a patient to inform clinical decision-making.
- Formulate an evidence-based treatment plan for managing the most common medical problems in patients with CKD, including anemia, CKD-related mineral and bone disorder, and hyperkalemia.
- Describe Medicare Part B and D policies related to end-stage renal disease (ESRD) and dialysis care (i.e., ESRD Prospective Payment System, Quality Incentive Program, Conditions for Coverage, Centers for Medicare & Medicaid Services Comprehensive ESRD Care Model) and their respective effects on medication use.

Dermatologic and Eyes, Ears, Nose, and Throat, and Immunologic Disorders - Module 6D

ACPE #: 0217-9999-22-067-H01-P

- Formulate an ophthalmologic drug therapy regimen for a patient presenting with macular degeneration, dry eye syndrome, or glaucoma.
- Construct an individualized pharmacy care plan for a patient with allergic rhinitis.
- Using a treatment algorithm, initiate, change, and modify topical and oral therapeutic regimens for acne.
- Recommend single or multiple topical and systemic agents for treating plaque psoriasis given a patient's disease presentation, severity, and prior therapies.
- Effectively educate a patient presenting with a skin infestation or minor burn on the purpose, proper use, and potential adverse reactions of the first-line treatment options.

Materials for this course will release 03/30/2022

Faculty

<https://www.rxcertifications.org/Ambulatory-Care/Course-Faculty>

Erica F. Crannage, Pharm.D., FCCP, BCPS, BCACP

Associate Professor
St. Louis College of Pharmacy at The University of Health
Sciences & Pharmacy;
Clinical Pharmacist
Mercy Clinic Family Medicine
St. Louis, Missouri

Spencer H. Durham, Pharm.D., BCPS, BCIDP

Associate Clinical Professor
Department of Pharmacy Practice
Auburn University Harrison School of Pharmacy
Auburn, Alabama

Jessica Farrell, Pharm.D.

Clinical Pharmacist
The Center for Rheumatology, LLC;
Associate Professor of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York

Alicia B. Forinash, Pharm.D., FCCP, BCPS, BCACP

Clinical Pharmacy Specialist
Maternal Fetal Care Center/WISH Center
SSM Health St. Mary's;
Professor of Pharmacy Practice
St. Louis College of Pharmacy at The University of Health
Sciences & Pharmacy
St. Louis, Missouri

Nicole M. Hahn, Pharm.D., BCACP*

Clinical Pharmacy Specialist – Neurology
Kaiser Permanente
Denver, Colorado

**Diana Isaacs, Pharm.D., FCCP, BCPS, BCACP, BC-ADM,
CDCES, ADCES**

Endocrine Clinical Pharmacy Specialist
CGM and Remote Monitoring Program Coordinator
Cleveland Clinic Endocrinology & Metabolism Institute
Cleveland, Ohio

Adam B. Jackson, Pharm.D., BCACP*

Clinical Pharmacy Specialist in Drug Utilization
Management
Pharmacy Department
Kaiser Permanente Colorado
Denver, Colorado

**Joel C. Marrs, Pharm.D., M.P.H., BCACP, BCCP, BCPS,
CHC, CLS, FAHA, FASHP, FCCP, FNLA**

Ambulatory Pharmacy Clinical Coordinator
Billings Clinic;
Clinical Associate Professor
Department of Pediatrics
University of Colorado School of Medicine
Aurora, Colorado

Michelle T. Martin, Pharm.D., FCCP, BCPS, BCACP

Clinical Pharmacist
University of Illinois Hospital & Health Sciences System;
Assistant Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Jamie L. McConaha, Pharm.D., BCACP*

Assistant Professor of Pharmacy Practice
Division of Pharmacy Practice
Duquesne University
Pittsburgh, Pennsylvania

Emily K. McCoy, Pharm.D., BCACP

Associate Clinical Professor
Auburn University Harrison School of Pharmacy
Mobile, Alabama

Molly G. Minze, Pharm.D., FCCP, BCACP

Associate Professor of Pharmacy Practice
Regional Director of Student Affairs and Admissions
Abilene Campus
Texas Tech University Health Sciences Center
Jerry H. Hodge School of Pharmacy
Abilene, Texas

Materials for this course will release 03/30/2022

Jean Y. Moon, Pharm.D., FCCP, BCACP

Associate Professor
PGY1 Residency Program Director
College of Pharmacy
University of Minnesota
Minneapolis, Minnesota

Melissa C. Palmer, Pharm.D., BCPS, BCPP

Clinical Pharmacy Specialist – Mental Health
Alaska VA Healthcare System
Anchorage, Alaska

Katie J. Suda, Pharm.D., M.S., FCCP

Professor
Department of Medicine
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Jessica Tilton, Pharm.D., BCACP

Clinical Assistant Professor
Clinical Pharmacist
Medication Therapy Management Clinic;
Clinical Coordinator
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

Elizabeth Van Dril, Pharm.D., BCPS, BCACP, CDCES

Clinical Assistant Professor
University of Illinois at Chicago College of Pharmacy
Chicago, Illinois

**Content Matter Experts*

Reviewers

Jennifer Banks, Pharm.D, BCPS, BCACP, BCGP, CDCES, BC-ADM, BCMTM, AE-C, CDP, CPh
Craig J. Beavers, Pharm.D., FCCP, FACC, FAHA, BCCP, BCPS-AQ Cardiology, CACP
Wiyanna K. Bruck, Pharm.D., BCIDP
Ashley N. Crawl, Pharm.D., BCACP
Frank A. Fanizza, Pharm.D., BCACP, AAHIVP
Melissa Lipari, Pharm.D., BCACP
Sarah A. McGill, Pharm.D., BCACP
Scott Pearson, Pharm.D., BCACP

Ann M. Philbrick, Pharm.D., FCCP, BCPS, BCACP
Melanie K. Proffitt, Pharm.D, BCACP, BCMTMS, MHA
Shelly L. Rutledge, Pharm.D, BCACP, INHC
Lindsay M. Saum, Pharm.D., BCPS, BCGP
Kyle V. Sheffer, Pharm.D., BCACP
Andrew J. Sowles, Pharm.D., BCPS, BCACP, BC-ADM
Sonal A. Taylor, Pharm.D., BCACP
Kris Denzel T. Tupas, Pharm.D., BCPS, BCACP
Susan R. Winkler, Pharm.D., FCCP, BCPS
Hilary Weismantel, Pharm.D., BCACP

Disclosures

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support and the Accreditation Council for Pharmacy Education's Standards for Commercial Support, ACCP and ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ACCP and ASHP education activities are qualified and selected by ACCP and ASHP required to disclose any relevant financial relationships with commercial interests. ACCP and ASHP identifies and resolves conflicts of interest prior to an individual's participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.

Materials for this course will release 03/30/2022

Faculty Disclosures:

- Consultant/Member of Advisory Board: Katie E. Cardone (AstraZeneca, Vifor, Otsuka, Wolters Kluwer), Spencer H. Durham (Shionogi Pharmaceuticals, Theratechnologies), Jessica Farrell (Cumberland Pharmaceuticals, Boehringer Ingelheim), Diana Isaacs (Lilly, Sanofi), Michelle T. Martin (AbbVie), Molly G. Minze (Wolters Kluwer)
- Grant Funding/Research Support: Jessica Farrell (Janssen Pharmaceuticals), Michelle T. Martin (Gilead, Merck), Melissa C. Palmer (Telehealth ECHO)
- Speaker's Bureau: Jessica Farrell (Pfizer, AbbVie), Michelle T. Martin (AbbVie), Diana Isaacs (Abbott, Bayer, Dexcom, Dexcom, Insulet, Medtronic, Nova Nordisk, Xeris Pharmaceuticals)
- Minor Shareholder: Michelle T. Martin (AbbVie, Gilead, and Merck), Jessica Tilton (Pfizer, Moderna, Viatrix)
- Other: Alicia B. Forinash (royalties from Wolters Kluwer)

Reviewer Disclosures:

- Consultant/Member of Advisory Board: Frank Fanizza (Guidepoint)

All the relevant financial relationships listed have been mitigated.

All other planners, presenters, reviewers, ACCP and ASHP staff and others with an opportunity to control content report no financial relationships relevant to this activity.

Methods and CE Requirements

Activities can be completed in any order. Each activity consists of audio, video, and/or PDFs and evaluations. Learners must review all content and complete the evaluations to receive continuing pharmacy education credit for each activity.

Follow the prompts to claim, view, or print the statement of credit within 60 days after completing the activity.

System Technical Requirements

Courses and learning activities are delivered via your Web browser and Acrobat PDF. For all activities, you should have a basic comfort level using a computer and navigating web sites.

View the [minimum technical and system requirements](#) for learning activities.

Development

These activities were developed by ACCP and ASHP.

To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for Board Certification Examinations.